Abstract
Tarlatamab (AMG 757) binds DLL3 on SCLC cells and CD3 on T cells leading to T cell-mediated tumor lysis. Updated phase 1 tarlatamab data in relapsed/refractory SCLC showed an ORR of 23%, median DOR of 13 months, and an acceptable safety profile with cytokine release syndrome (CRS) as the most common treatment-related (TRAE).1 Here, we describe clinical CRS seen with tarlatamab and explore associations between cytokine levels and CRS in cycle 1 (C1)-where CRS mostly occurs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
